|
Public |
|
| Healthcare & Pharmaceuticals - Medical Devices | |
| around $10 - 20M | |
| around 100 - 250 | |
| www.durect.com | |
| (408) 777-1417 | |
| (408) 777-3577 | |
Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company?s product pipeline consists of seven investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), one program in Phase III, two programs in Phase II and three programs in Phase I. The Company?s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its pharmaceutical systems technologies to products in a range of chronic and episodic disease areas, including pain, cent... (Source: SEC reports)
Competitor - 1/8
Which company is more competitive with DURECT Corporation?
Oct 2, 2018 06:47:49
CUPERTINO, Calif., Oct. 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Michael H. Arenberg to the position of Chief Financial Officer, effective October 15, 2018. [...]
Oct 2, 2017 20:13:09
CUPERTINO, Calif., Oct. 2, 2017 /PRNewswire/ --Â DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (LON: INDV), [...]
Sep 20, 2017 08:42:29
CUPERTINO, Calif., Sept. 20, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development. Â Dr. [...]
Sep 5, 2017 20:43:18
CUPERTINO, Calif., Sept. 5, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences. A live [...]
Aug 8, 2017 20:43:16
CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/ --Â DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update. [...]